피부과 처방약 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Prescription Dermatology Therapeutics Market - Scope of Report

TMR's report on the global prescription dermatology therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global prescription dermatology therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global prescription dermatology therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the prescription dermatology therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global prescription dermatology therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global prescription dermatology therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global prescription dermatology therapeutics market.

The report delves into the competitive landscape of the global prescription dermatology therapeutics market. Key players operating in the global prescription dermatology therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global prescription dermatology therapeutics market profiled in this report.

Key Questions Answered in Global prescription dermatology therapeutics Market Report:

• What is the sales/revenue generated by prescription dermatology therapeutics across all regions during the forecast period?
• What are the opportunities in the global prescription dermatology therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Prescription Dermatology Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global prescription dermatology therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global prescription dermatology therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global prescription dermatology therapeutics market.

Table of Contents

1. Executive Summary

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Prescription Dermatology Therapeutics Market

4. Market Overview

• 4.1. Market Segmentation
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
• 5.3. COVID-19 Pandemic Impact on Industry

6. Prescription Dermatology Therapeutics Market Analysis and Forecast, by Product Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product Type, 2017-2031
  • 6.3.1. Acne & Rosacea Drugs
  • 6.3.2. Psoriasis Drugs
  • 6.3.3. Dermatitis & Seborrhea Drugs
  • 6.3.4. Fungal Infection Drugs
  • 6.3.5. Skin Cancer Drugs
  • 6.3.6. Others
• 6.4. Market Attractiveness, by Product Type

7. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Mail Order Pharmacies
• 7.4. Market Attractiveness, by Distribution Channel

8. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region, 2017-2031
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness, by Region

9. North America Prescription Dermatology Therapeutics Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast, by Product Type, 2017-2031
  • 9.2.1. Acne & Rosacea Drugs
  • 9.2.2. Psoriasis Drugs
  • 9.2.3. Dermatitis & Seborrhea Drugs
  • 9.2.4. Fungal Infection Drugs
  • 9.2.5. Skin Cancer Drugs
  • 9.2.6. Others
• 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Mail Order Pharmacies
• 9.4. Market Value Forecast, by Country, 2017-2031
  • 9.4.1. U.S.
  • 9.4.2. Canada
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Product Type
  • 9.5.2. By Distribution Channel
  • 9.5.3. By Country

10. Europe Prescription Dermatology Therapeutics Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Product Type, 2017-2031
  • 10.2.1. Acne & Rosacea Drugs
  • 10.2.2. Psoriasis Drugs
  • 10.2.3. Dermatitis & Seborrhea Drugs
  • 10.2.4. Fungal Infection Drugs
  • 10.2.5. Skin Cancer Drugs
  • 10.2.6. Others
• 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Mail Order Pharmacies
• 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.4.1. Germany
  • 10.4.2. U.K.
  • 10.4.3. France
  • 10.4.4. Italy
  • 10.4.5. Spain
  • 10.4.6. Rest of Europe
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Product Type
  • 10.5.2. By Distribution Channel
  • 10.5.3. By Country/Sub-region

11. Asia Pacific Prescription Dermatology Therapeutics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product Type, 2017-2031
  • 11.2.1. Acne & Rosacea Drugs
  • 11.2.2. Psoriasis Drugs
  • 11.2.3. Dermatitis & Seborrhea Drugs
  • 11.2.4. Fungal Infection Drugs
  • 11.2.5. Skin Cancer Drugs
  • 11.2.6. Others
• 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Mail Order Pharmacies
• 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.4.1. China
  • 11.4.2. Japan
  • 11.4.3. India
  • 11.4.4. Australia & New Zealand
  • 11.4.5. Rest of Asia Pacific
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Product Type
  • 11.5.2. By Distribution Channel
  • 11.5.3. By Country/Sub-region

12. Latin America Prescription Dermatology Therapeutics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product Type, 2017-2031
  • 12.2.1. Acne & Rosacea Drugs
  • 12.2.2. Psoriasis Drugs
  • 12.2.3. Dermatitis & Seborrhea Drugs
  • 12.2.4. Fungal Infection Drugs
  • 12.2.5. Skin Cancer Drugs
  • 12.2.6. Others
• 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.3.1. Hospital Pharmacies
  • 12.3.2. Retail Pharmacies
  • 12.3.3. Mail Order Pharmacies
• 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.4.1. Brazil
  • 12.4.2. Mexico
  • 12.4.3. Rest of Latin America
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Product Type
  • 12.5.2. By Distribution Channel
  • 12.5.3. By Country/Sub-region

13. Middle East & Africa Prescription Dermatology Therapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product Type, 2017-2031
  • 13.2.1. Acne & Rosacea Drugs
  • 13.2.2. Psoriasis Drugs
  • 13.2.3. Dermatitis & Seborrhea Drugs
  • 13.2.4. Fungal Infection Drugs
  • 13.2.5. Skin Cancer Drugs
  • 13.2.6. Others
• 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.3.1. Hospital Pharmacies
  • 13.3.2. Retail Pharmacies
  • 13.3.3. Mail Order Pharmacies
• 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.4.1. GCC Countries
  • 13.4.2. South Africa
  • 13.4.3. Rest of Middle East & Africa
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Product Type
  • 13.5.2. By Distribution Channel
  • 13.5.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 14.2. Market Share Analysis, by Company (2022)
• 14.3. Company Profiles
  • 14.3.1. AbbVie, Inc.
    • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.1.2. Product Type Portfolio
    • 14.3.1.3. Financial Overview
    • 14.3.1.4. SWOT Analysis
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Janssen Biotech, Inc.
    • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.2.2. Product Type Portfolio
    • 14.3.2.3. Financial Overview
    • 14.3.2.4. SWOT Analysis
    • 14.3.2.5. Strategic Overview
  • 14.3.3. Novartis AG
    • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.3.2. Product Type Portfolio
    • 14.3.3.3. Financial Overview
    • 14.3.3.4. SWOT Analysis
    • 14.3.3.5. Strategic Overview
  • 14.3.4. Amgen, Inc.
    • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.4.2. Product Type Portfolio
    • 14.3.4.3. Financial Overview
    • 14.3.4.4. SWOT Analysis
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Celgene Corporation
    • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.5.2. Product Type Portfolio
    • 14.3.5.3. Financial Overview
    • 14.3.5.4. SWOT Analysis
    • 14.3.5.5. Strategic Overview
  • 14.3.6. Pfizer Inc.
    • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.6.2. Product Type Portfolio
    • 14.3.6.3. Financial Overview
    • 14.3.6.4. SWOT Analysis
    • 14.3.6.5. Strategic Overview
  • 14.3.7. LEO Pharma A/S
    • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.7.2. Product Type Portfolio
    • 14.3.7.3. Financial Overview
    • 14.3.7.4. SWOT Analysis
    • 14.3.7.5. Strategic Overview
  • 14.3.8. Eli Lilly and Company
    • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.8.2. Product Type Portfolio
    • 14.3.8.3. Financial Overview
    • 14.3.8.4. SWOT Analysis
    • 14.3.8.5. Strategic Overview
  • 14.3.9. Bausch Health Companies, Inc.
    • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.9.2. Product Type Portfolio
    • 14.3.9.3. Financial Overview
    • 14.3.9.4. SWOT Analysis
    • 14.3.9.5. Strategic Overview
  • 14.3.10. Sun Pharmaceuticals Ltd.
    • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.10.2. Product Type Portfolio
    • 14.3.10.3. Financial Overview
    • 14.3.10.4. SWOT Analysis
    • 14.3.10.5. Strategic Overview
  • 14.3.11. Aclaris Therapeutics, Inc.
    • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.11.2. Product Type Portfolio
    • 14.3.11.3. Financial Overview
    • 14.3.11.4. SWOT Analysis
    • 14.3.11.5. Strategic Overview
  • 14.3.12. Aurobindo Pharma Ltd.
    • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.12.2. Product Type Portfolio
    • 14.3.12.3. Financial Overview
    • 14.3.12.4. SWOT Analysis
    • 14.3.12.5. Strategic Overview